Related Experiment Video
Updated: May 25, 2026

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)
Published on: September 11, 2012
Acute sensitization of colon cancer cells to inflammatory cytokines by prophase arrest
Anton Kuratnik1, Virginia E Senapati, Rajeev Verma
1Department of Molecular and Cell Biology, 91 North Eagleville Road, University of Connecticut, Storrs, CT 06269, United States.
Abstract:
Understanding how colon cancer cells survive within the inflammatory milieu of a tumor, and developing approaches that increase their sensitivity to inflammatory cytokines, may ultimately lead to novel approaches for colon cancer therapy and prevention. Analysis of a number of chemopreventive and therapeutic agents reveal that HDAC inhibitors are particularly adept at sensitizing colon cancer cells TNF or TRAIL mediated apoptosis. In vivo data are consistent with an interaction between SAHA and TNF in inducing apoptosis, as AOM-induced colon tumors express elevated levels of TNF and are more sensitive to SAHA administration. Cell cycle analysis and time-lapse imaging indicated a close correspondence between SAHA-induced prophase arrest and TNF or TRAIL-induced apoptosis. Prophase arrest induced by the Aurora kinase inhibitor VX680 likewise sensitized cells to TNF and TRAIL, with siRNA analysis pointing to Aurora kinase A (and not Aurora kinase B) as being the relevant target for this sensitization. We propose that agents that promote prophase arrest may help sensitize cancer cells to TNF and other inflammatory cytokines. We also discuss how circumvention of an early mitotic checkpoint may facilitate cancer cell survival in the inflammatory micro-environment of the tumor.
Insights
Histone deacetylase inhibitors sensitize colon cancer cells to inflammatory cytokines like TNF and TRAIL by inducing prophase arrest. This finding offers potential new strategies for colon cancer therapy and prevention.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Cell Biology
Background:
- Colon cancer cells thrive in inflammatory tumor environments.
- Developing strategies to enhance cancer cell sensitivity to inflammatory cytokines is crucial for effective therapy.
Purpose of the Study:
- To investigate how colon cancer cells survive within the tumor's inflammatory milieu.
- To identify therapeutic agents that sensitize colon cancer cells to inflammatory cytokines, such as tumor necrosis factor (TNF) and TNF-related apoptosis-inducing ligand (TRAIL).
Main Methods:
- Analysis of chemopreventive and therapeutic agents, focusing on histone deacetylase (HDAC) inhibitors.
- In vivo studies using AOM-induced colon tumors.
- Cell cycle analysis and time-lapse imaging.
- siRNA analysis targeting Aurora kinases.
Main Results:
- HDAC inhibitors, specifically SAHA (suberoylanilide hydroxamic acid), effectively sensitize colon cancer cells to TNF- and TRAIL-mediated apoptosis.
- SAHA administration enhances apoptosis in AOM-induced colon tumors, which exhibit elevated TNF levels.
- SAHA-induced prophase arrest closely correlates with TNF- or TRAIL-induced apoptosis.
- The Aurora kinase inhibitor VX680 also sensitizes cells to TNF and TRAIL, with Aurora kinase A identified as the key mediator.
Conclusions:
- Agents that induce prophase arrest may sensitize cancer cells to inflammatory cytokines like TNF.
- Circumvention of early mitotic checkpoints may contribute to cancer cell survival in inflammatory tumor microenvironments.
- These findings suggest novel therapeutic and preventive strategies for colon cancer by targeting inflammatory pathways and cell cycle regulation.
Related Concept Videos
Inflammatory Bowel Disease III: Crohn's Disease
Anaphase Promoting Complex
Inflammatory Bowel Disease II: Ulcerative Colitis
Separation of Sister Chromatids
At the onset of anaphase, separase, a proteolytic enzyme, is...
Cancer Cell Migration through Invadopodia
DNA Damage can Stall the Cell Cycle

